BACKGROUND AND AIMS: Inflammatory bowel disease is characterised by oxidative and nitrosative stress, leucocyte infiltration, upregulation of expression of intercellular adhesion molecule 1 (ICAM-1), and upregulation of P-selectin in the colon. The aim of the present study was to examine the effects of calpain inhibitor I in rats subjected to experimental colitis. METHODS: Colitis was induced in rats by intracolonic instillation of dinitrobenzene sulphonic acid (DNBS). RESULTS: Rats experienced haemorrhagic diarrhoea and weight loss. Four days after administration of DNAB, the mucosa of the colon exhibited large areas of necrosis. Neutrophil infiltration (determined by histology as well as by an increase in myeloperoxidase activity in the mucosa) was associated with upregulation of ICAM-1 and P-selectin as well as high tissue levels of malondialdehyde. Immunohistochemistry for nitrotyrosine and poly (ADP-ribose) polymerase (PARP) showed intense staining in the inflamed colon. Staining of sections of colon obtained from DNBS treated rats with an anti-cyclooxygenase 2 antibody showed diffuse staining of the inflamed tissue. Furthermore, expression of inducible nitric oxide synthase was found mainly in macrophages located within the inflamed colon of DNBS treated rats. Calpain inhibitor I (5 mg/kg daily intraperitoneally) significantly reduced the degree of haemorrhagic diarrhoea and weight loss caused by administration of DNBS. Calpain inhibitor I also caused a substantial reduction in (i) degree of colon injury, (ii) rise in myeloperoxidase activity (mucosa), (iii) increase in tissue levels of malondialdehyde, (iv) increase in staining (immunohistochemistry) for nitrotyrosine and PARP, as well as (v) upregulation of ICAM-1 and P-selectin caused by DNBS in the colon. CONCLUSION: Calpain inhibitor I reduces the degree of colitis caused by DNBS. We propose that calpain inhibitor I may be useful in the treatment of inflammatory bowel disease.
BACKGROUND AND AIMS: Inflammatory bowel disease is characterised by oxidative and nitrosative stress, leucocyte infiltration, upregulation of expression of intercellular adhesion molecule 1 (ICAM-1), and upregulation of P-selectin in the colon. The aim of the present study was to examine the effects of calpain inhibitor I in rats subjected to experimental colitis. METHODS:Colitis was induced in rats by intracolonic instillation of dinitrobenzene sulphonic acid (DNBS). RESULTS:Rats experienced haemorrhagic diarrhoea and weight loss. Four days after administration of DNAB, the mucosa of the colon exhibited large areas of necrosis. Neutrophil infiltration (determined by histology as well as by an increase in myeloperoxidase activity in the mucosa) was associated with upregulation of ICAM-1 and P-selectin as well as high tissue levels of malondialdehyde. Immunohistochemistry for nitrotyrosine and poly (ADP-ribose) polymerase (PARP) showed intense staining in the inflamed colon. Staining of sections of colon obtained from DNBS treated rats with an anti-cyclooxygenase 2 antibody showed diffuse staining of the inflamed tissue. Furthermore, expression of inducible nitric oxide synthase was found mainly in macrophages located within the inflamed colon of DNBS treated rats. Calpain inhibitor I (5 mg/kg daily intraperitoneally) significantly reduced the degree of haemorrhagic diarrhoea and weight loss caused by administration of DNBS. Calpain inhibitor I also caused a substantial reduction in (i) degree of colon injury, (ii) rise in myeloperoxidase activity (mucosa), (iii) increase in tissue levels of malondialdehyde, (iv) increase in staining (immunohistochemistry) for nitrotyrosine and PARP, as well as (v) upregulation of ICAM-1 and P-selectin caused by DNBS in the colon. CONCLUSION: Calpain inhibitor I reduces the degree of colitis caused by DNBS. We propose that calpain inhibitor I may be useful in the treatment of inflammatory bowel disease.
Authors: Y Harada; K Hatanaka; M Kawamura; M Saito; M Ogino; M Majima; T Ohno; K Ogino; K Yamamoto; Y Taketani; S Yamamoto; M Katori Journal: Prostaglandins Date: 1996-01
Authors: L Lih-Brody; S R Powell; K P Collier; G M Reddy; R Cerchia; E Kahn; G S Weissman; S Katz; R A Floyd; M J McKinley; S E Fisher; G E Mullin Journal: Dig Dis Sci Date: 1996-10 Impact factor: 3.199
Authors: I Ikeda; T Kasajima; S Ishiyama; T Shimojo; Y Takeo; T Nishikawa; S Kameoka; M Hiroe; A Mitsunaga Journal: Am J Gastroenterol Date: 1997-08 Impact factor: 10.864
Authors: Xiaorong Zhu; Jeannette S Messer; Yunwei Wang; Fanfei Lin; Candace M Cham; Jonathan Chang; Timothy R Billiar; Michael T Lotze; David L Boone; Eugene B Chang Journal: J Clin Invest Date: 2015-02-02 Impact factor: 14.808
Authors: Salvatore Cuzzocrea; Emanuela Mazzon; Rosanna Di Paola; Tiziana Genovese; Nimesh S A Patel; Carmelo Muià; Michael D Threadgill; Angelina De Sarro; Christoph Thiemermann Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2004-11-18 Impact factor: 3.000
Authors: Aaron H Rose; Zhi Huang; Chrisy Mafnas; Jared H Hara; FuKun W Hoffmann; Ann S Hashimoto; Pietro Bertino; Peter R Hoffmann Journal: Inflamm Bowel Dis Date: 2015-09 Impact factor: 5.325
Authors: G D'Argenio; M Calvani; N Della Valle; V Cosenza; G Di Matteo; P Giorgio; S Margarucci; O Petillo; F P Jori; U Galderisi; G Peluso Journal: Gut Date: 2005-04 Impact factor: 23.059
Authors: Zhi Huang; Aaron H Rose; FuKun W Hoffmann; Ann S Hashimoto; Pietro Bertino; Tobias Denk; Jiro Takano; Nobuhisa Iwata; Takaomi C Saido; Peter R Hoffmann Journal: J Immunol Date: 2013-08-28 Impact factor: 5.422
Authors: Ioannis Virlos; Emanuela Mazzon; Ivana Serraino; Tiziana Genovese; Rosanna Di Paola; Christoph Thiemerman; Ajith Siriwardena; Salvatore Cuzzocrea Journal: Intensive Care Med Date: 2004-05-27 Impact factor: 17.440
Authors: Shrikant V Joshi; Bhavin A Vyas; Payal D Shah; Dinesh R Shah; Shailesh A Shah; Tejal R Gandhi Journal: Indian J Pharmacol Date: 2011-11 Impact factor: 1.200